IDH1 and cholangiocarcinoma: Results of a phase 1 study suggest that ivosidenib is a well-tolerated option in patients with IDH1-variant cholangiocarcinoma [35], and phase 3 study shows progression-free survival was significantly improved with ivosidenib compared with placebo in advanced, IDH1-mutant cholangiocarcinoma [36].